An observational study in Cerebrospinal; Disorder, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 7 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-05.
Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Central Nervous System Diseases with a site in France — 15 open to participants now, 17 under way, 1 of them phase 3. Central Nervous System Diseases · France.
Among the 46 studies in Central Nervous System Diseases with a site in France, this one is the 9th largest by planned enrollment of the 12 observational ones that give a count, is one of 8 that started in 2023, is one of 12 observational ones, reaches primary completion later than 1 of the 16 other live ones, and was the 35th registered.
386 studies on the registry are indexed under Central Nervous System Diseases; 104 are open to participants now.
Browse Central Nervous System Diseases studies →15 of the 46 studies in Central Nervous System Diseases with a site in France are open now. Recruiting first, the newest first:
MapLight Therapeutics · Sites in France, United States, Argentina and 12 more countries
Ages 55–90
University Hospital, Rouen · Sites in France
Healthy volunteers
iECURE, Inc. · Sites in France, United States, United Kingdom
Ages 7 mo–15 mo
University Hospital, Limoges · Sites in France
Ages 35–75
REGEnLIFE SAS · Sites in France
Ages 55–85
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 76 Central Nervous System Diseases studies recruiting now, 34 (45%) set no upper age limit and 22 (29%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 13
First in 2008; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 139 across 73 observational studies indexed under Central Nervous System Diseases.
Median enrollment 183 across the 34 interventional studies, 110 across the 12 observational. Of the 28 that completed or were terminated, 14 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 598 studies on the registry; 128 are open to participants now.
Centre Hospitalier Universitaire de Saint Etienne has 1 study filed under Central Nervous System Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Central Nervous System Diseases with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04194619Hospices Civils de LyonPregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study | 2027-02 |
| NCT06053619University Hospital, LimogesTolerance Study of Robotic-Assisted Virtual Reality Walking Rehabilitation for Non-Walking Stroke Patients | 2027-03-11 |
| NCT05926011REGEnLIFE SASEfficacy of RGn600 in Patients With Mild-to-moderate Alzheimer's Disease | 2027-06 |
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies in Central Nervous System Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Despite the massive use of intracranial pressure in neuro-resuscitation, there is still no cerebral compliance evaluation index used in current practice to guide therapy.
In treatment guidelines for intracranial hypertension, patients are placed in a prone position at about 30 degrees. Several times a day, during nursing care, patients are flattened, which corresponds to a cerebral compliance test by adding a volume of cerebrospinal fluid to the cranial box.
This study aims to analyse the shape of the different components of the intracranial pressure waves (P1, P2, and P3) when the patient is flattened to determine an index to define the level of cerebral compliance.
Sedated patient on mechanical ventilation with continuous intracranial pressure monitoring
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Post-retrieval from the medical record
Post-retrieval from the medical record
Post-retrieval of ICP values from the monitor
Intracranial pressure (mmHg)
Intracranial pressure is measured before (Raising the head by 30°) and during the flattening (Raising the head by 0°). Theses measures are done twice a day. The mean of theses values is calculated.
Time frame: Year : 1
Correlation between ICP (Intra Cranial Pressure) doses and cerebral compliance
Compare the ICP (Intra Cranial Pressure) dose value with the compliance index during the period before or after the flattening
Time frame: Year : 1
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Apr 2024, 13 months after the start.
Of 39 observational studies under Central Nervous System Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 121. This study's planned 13 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Nervous System Diseases →
Centre Hospitalier Universitaire de Saint Etienne →